Status:
UNKNOWN
Desensitization With Bortezomib Before a Living Kidney Donation
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Patients Awaiting a Living Kidney Donation
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The investigators plan to study the role of bortezomib for desensitizing patients awaiting a living kidney donation who have a titer of Donor Specific anti human leucocyte antigen (HLA) Antibody (DSA)...
Detailed Description
The investigators plan to study the role of bortezomib for desensitizing patients awaiting a living kidney donation who have a titer of Donor Specific anti HLA Antibody (DSA) between 1000 and 3000 MFI...
Eligibility Criteria
Inclusion
- Patient between 18 and 70 years old
- awaiting a living kidney donation
- but with a least one DSA titer between 1000 MFI and 3000 MFI
Exclusion
- positive cell dependent cytotoxicity CM,
- DSA level above 3000 MFI
- and every condition that is a contre indication for bortezomib treatment
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2018
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01842074
Start Date
March 1 2013
End Date
March 1 2018
Last Update
September 29 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique - Hôpitaux de Paris, Bicêtre Hospital
Le Kremlin-Bicêtre, France, 94 275